From wearables to gaming platforms that measure disease symptoms and treatment outcomes, we're deploying digital health technology (DHT) tools that enable unprecedented data gathering and insights that inform our drug development process.
For diseases that are challenging to develop new therapies, our new tools help enable the development of objective and sensitive digital biomarkers — which aim to improve our ability to identify treatment responders faster and make clinical assessments more precise.
We also measure some outcomes in the real-world setting through connected sensor technology alongside COAs to provide a holistic understanding of patient experience. For example, we measure improvements in physical activity, sleep, and joint range of motion upon treatment in rheumatic conditions. In dermatological indications, images can be captured and assessed in real-time, enabling evidence-based treatment discussions based on disease activity.